KYG2524A1031
KYG2524A1031
CONSUN PHARMA
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 3.417.355.000 | 2.967.235.000 | 15.2% |
| Cost of Revenue | 750.235.000 | 725.133.000 | 3.5% |
| Gross Profit | 2.667.120.000 | 2.242.102.000 | 19.0% |
| 1.514.736.000 | 1.279.333.000 | 18.4% | |
| Operating Income | 1.152.384.000 | 962.769.000 | 19.7% |
| Pretax Income | 1.196.422.000 | 1.020.106.000 | 17.3% |
| Net Income Common Stockholders | 1.078.067.000 | 910.458.000 | 18.4% |
| -- | -- | -- | |
| -- | -- | -- |